Xtuit was a private biopharmaceutical based in Waltham, United States. The company specialized in developing microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, a key driver in cancer progression. The company advanced multiple treatments for cancer and fibrotic diseases.
Cancer & fibrotic diseases
CTI LSF II
Syndicate
Director
September 25, 2016
Liquidated in 2018
Series A
Xtuit was based on scientific foundation from Harvard and MIT and had data demonstrating their lead candidate could reverse disease progression
June 11, 2015
